
## Patricia A Ganz

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3277206/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Fatigue in Breast Cancer Survivors: Occurrence, Correlates, and Impact on Quality of Life. Journal of Clinical Oncology, 2000, 18, 743-743.	1.6	960
2	Quality of Life in Long-Term, Disease-Free Survivors of Breast Cancer: a Follow-up Study. Journal of the National Cancer Institute, 2002, 94, 39-49.	6.3	850
3	American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options. Journal of Clinical Oncology, 2015, 33, 2563-2577.	1.6	783
4	Adjuvant Olaparib for Patients with <i>BRCA1</i> - or <i>BRCA2</i> -Mutated Breast Cancer. New England Journal of Medicine, 2021, 384, 2394-2405.	27.0	764
5	Quality of Life, Fertility Concerns, and Behavioral Health Outcomes in Younger Breast Cancer Survivors: A Systematic Review. Journal of the National Cancer Institute, 2012, 104, 386-405.	6.3	659
6	American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. Journal of Clinical Oncology, 2016, 34, 611-635.	1.6	651
7	Fatigue in longâ€ŧerm breast carcinoma survivors. Cancer, 2006, 106, 751-758.	4.1	586
8	Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received. Journal of Clinical Oncology, 2016, 34, 2925-2934.	1.6	538
9	American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. Ca-A Cancer Journal for Clinicians, 2016, 66, 43-73.	329.8	497
10	Screening, Assessment, and Management of Fatigue in Adult Survivors of Cancer: An American Society of Clinical Oncology Clinical Practice Guideline Adaptation. Journal of Clinical Oncology, 2014, 32, 1840-1850.	1.6	486
11	Role of Breast Reconstructive Surgery in Physical and Emotional Outcomes Among Breast Cancer Survivors. Journal of the National Cancer Institute, 2000, 92, 1422-1429.	6.3	481
12	Fatigue and Proinflammatory Cytokine Activity in Breast Cancer Survivors. Psychosomatic Medicine, 2002, 64, 604-611.	2.0	467
13	Breast Cancer in Younger Women: Reproductive and Late Health Effects of Treatment. Journal of Clinical Oncology, 2003, 21, 4184-4193.	1.6	437
14	Quality of Life at the End of Primary Treatment of Breast Cancer: First Results From the Moving Beyond Cancer Randomized Trial. Journal of the National Cancer Institute, 2004, 96, 376-387.	6.3	429
15	Inflammation and Behavioral Symptoms After Breast Cancer Treatment: Do Fatigue, Depression, and Sleep Disturbance Share a Common Underlying Mechanism?. Journal of Clinical Oncology, 2011, 29, 3517-3522.	1.6	414
16	Cognitive Impairment Associated With Chemotherapy for Cancer: Report of a Workshop. Journal of Clinical Oncology, 2004, 22, 2233-2239.	1.6	400
17	Association of Type and Location of <i>BRCA1</i> and <i>BRCA2</i> Mutations With Risk of Breast and Ovarian Cancer. JAMA - Journal of the American Medical Association, 2015, 313, 1347.	7.4	390
18	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nature Genetics, 2017, 49, 680-691.	21.4	356

#	Article	IF	CITATIONS
19	Inflammatory Biomarkers for Persistent Fatigue in Breast Cancer Survivors. Clinical Cancer Research, 2006, 12, 2759-2766.	7.0	351
20	Altered frontocortical, cerebellar, and basal ganglia activity in adjuvant-treated breast cancer survivors 5–10Âyears after chemotherapy. Breast Cancer Research and Treatment, 2007, 103, 303-311.	2.5	349
21	CAncer rehabilitation evaluation system–short form (CARES-SF). A cancer specific rehabilitation and quality of life instrument. Cancer, 1991, 68, 1406-1413.	4.1	341
22	Neurocognitive Performance in Breast Cancer Survivors Exposed to Adjuvant Chemotherapy and Tamoxifen. Journal of Clinical and Experimental Neuropsychology, 2004, 26, 955-969.	1.3	338
23	Quality of life assessment. An independent prognostic variable for survival in lung cancer. Cancer, 1991, 67, 3131-3135.	4.1	331
24	Predictors of Sexual Health in Women After a Breast Cancer Diagnosis. Journal of Clinical Oncology, 1999, 17, 2371-2371.	1.6	324
25	Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial. Lancet, The, 2019, 394, 2155-2164.	13.7	319
26	Breast conservationversus mastectomy. Is there a difference in psychological adjustment or quality of life in the year after surgery?. Cancer, 1992, 69, 1729-1738.	4.1	303
27	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nature Genetics, 2017, 49, 1767-1778.	21.4	289
28	Managing Menopausal Symptoms in Breast Cancer Survivors: Results of a Randomized Controlled Trial. Journal of the National Cancer Institute, 2000, 92, 1054-1064.	6.3	281
29	Mindfulness meditation for younger breast cancer survivors: A randomized controlled trial. Cancer, 2015, 121, 1231-1240.	4.1	267
30	Inflammatory Biomarkers and Fatigue during Radiation Therapy for Breast and Prostate Cancer. Clinical Cancer Research, 2009, 15, 5534-5540.	7.0	264
31	Breast Cancer in Older Women: Quality of Life and Psychosocial Adjustment in the 15 Months After Diagnosis. Journal of Clinical Oncology, 2003, 21, 4027-4033.	1.6	227
32	Identifying and Addressing the Needs of Adolescents and Young Adults With Cancer: Summary of an Institute of Medicine Workshop. Oncologist, 2015, 20, 186-195.	3.7	224
33	Mutational spectrum in a worldwide study of 29,700 families with <i>BRCA1</i> or <i>BRCA2</i> mutations. Human Mutation, 2018, 39, 593-620.	2.5	224
34	Psychologic Distress and Natural Menopause: A Multiethnic Community Study. American Journal of Public Health, 2001, 91, 1435-1442.	2.7	221
35	Yoga reduces inflammatory signaling in fatigued breast cancer survivors: A randomized controlled trial. Psychoneuroendocrinology, 2014, 43, 20-29.	2.7	211
36	Interventions to Address Sexual Problems in People With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Adaptation of Cancer Care Ontario Guideline. Journal of Clinical Oncology, 2018, 36, 492-511.	1.6	208

#	Article	IF	CITATIONS
37	Physical and Psychosocial Recovery in the Year After Primary Treatment of Breast Cancer. Journal of Clinical Oncology, 2011, 29, 1101-1109.	1.6	207
38	Altered Cortisol Response to Psychologic Stress in Breast Cancer Survivors With Persistent Fatigue. Psychosomatic Medicine, 2005, 67, 277-280.	2.0	195
39	New Fibrate Use and Acute Renal Outcomes in Elderly Adults. Annals of Internal Medicine, 2012, 156, 560.	3.9	192
40	Survivorship: Adult Cancer Survivors. Primary Care - Clinics in Office Practice, 2009, 36, 721-741.	1.6	191
41	Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With <i>BRCA</i> Mutations. JAMA Oncology, 2016, 2, 1434.	7.1	189
42	Promoting adjustment after treatment for cancer. Cancer, 2005, 104, 2608-2613.	4.1	185
43	Quality of life of African-American and white long term breast carcinoma survivors. , 1999, 85, 418-426.		177
44	Cognitive Complaints After Breast Cancer Treatments: Examining the Relationship With Neuropsychological Test Performance. Journal of the National Cancer Institute, 2013, 105, 791-801.	6.3	173
45	Results of the Exercise and Nutrition to Enhance Recovery and Good Health for You (ENERGY) Trial: A Behavioral Weight Loss Intervention in Overweight or Obese Breast Cancer Survivors. Journal of Clinical Oncology, 2015, 33, 3169-3176.	1.6	173
46	A Standard Set of Value-Based Patient-Centered Outcomes for Breast Cancer. JAMA Oncology, 2017, 3, 677.	7.1	167
47	Provision and Discussion of Survivorship Care Plans Among Cancer Survivors: Results of a Nationally Representative Survey of Oncologists and Primary Care Physicians. Journal of Clinical Oncology, 2014, 32, 1578-1585.	1.6	163
48	The BCPT Symptom Scales: A Measure of Physical Symptoms for Women Diagnosed With or at Risk for Breast Cancer. Journal of the National Cancer Institute, 2005, 97, 448-456.	6.3	154
49	Future cancer research priorities in the USA: a Lancet Oncology Commission. Lancet Oncology, The, 2017, 18, e653-e706.	10.7	153
50	Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial. Lancet, The, 2016, 387, 849-856.	13.7	148
51	Fatigue and gene expression in human leukocytes: Increased NF-κB and decreased glucocorticoid signaling in breast cancer survivors with persistent fatigue. Brain, Behavior, and Immunity, 2011, 25, 147-150.	4.1	145
52	Sexuality following breast cancer. Journal of Sex and Marital Therapy, 1999, 25, 237-250.	1.5	144
53	Life after diagnosis and treatment of cancer in adulthood: Contributions from psychosocial oncology research American Psychologist, 2015, 70, 159-174.	4.2	144
54	Does tumor necrosis factor-alpha (TNF-α) play a role in post-chemotherapy cerebral dysfunction?. Brain, Behavior, and Immunity, 2013, 30, S99-S108.	4.1	143

#	Article	IF	CITATIONS
55	Clinical Cancer Advances 2016: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology, Journal of Clinical Oncology, 2016, 34, 987-1011.	1.6	141
56	Tai Chi Chih Compared With Cognitive Behavioral Therapy for the Treatment of Insomnia in Survivors of Breast Cancer: A Randomized, Partially Blinded, Noninferiority Trial. Journal of Clinical Oncology, 2017, 35, 2656-2665.	1.6	139
57	Late effects of cancer and its treatment. Seminars in Oncology Nursing, 2001, 17, 241-248.	1.5	131
58	Sleep disturbance, inflammation and depression risk in cancer survivors. Brain, Behavior, and Immunity, 2013, 30, S58-S67.	4.1	126
59	Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. Nature Genetics, 2016, 48, 374-386.	21.4	125
60	Examining the influence of beta blockers and ACE inhibitors on the risk for breast cancer recurrence: results from the LACE cohort. Breast Cancer Research and Treatment, 2011, 129, 549-556.	2.5	124
61	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. Nature Genetics, 2020, 52, 56-73.	21.4	120
62	Going Beyond Being Lost in Transition: A Decade of Progress in Cancer Survivorship. Journal of Clinical Oncology, 2017, 35, 1978-1981.	1.6	118
63	Effect of Depression on Diagnosis, Treatment, and Mortality of Men With Clinically Localized Prostate Cancer. Journal of Clinical Oncology, 2014, 32, 2471-2478.	1.6	115
64	Monitoring the Physical Health of Cancer Survivors: A Survivorship-Focused Medical History. Journal of Clinical Oncology, 2006, 24, 5105-5111.	1.6	113
65	Tai Chi, Cellular Inflammation, and Transcriptome Dynamics in Breast Cancer Survivors With Insomnia: A Randomized Controlled Trial. Journal of the National Cancer Institute Monographs, 2014, 2014, 295-301.	2.1	113
66	Menstrual History and Quality-of-Life Outcomes in Women With Node-Positive Breast Cancer Treated With Adjuvant Therapy on the NSABP B-30 Trial. Journal of Clinical Oncology, 2011, 29, 1110-1116.	1.6	108
67	Suicide After Breast Cancer: an International Population-Based Study of 723 810 Women. Journal of the National Cancer Institute, 2006, 98, 1416-1419.	6.3	106
68	Young adult cancer survivors and work: a systematic review. Journal of Cancer Survivorship, 2017, 11, 765-781.	2.9	99
69	Comparative Effectiveness of Robot-assisted Versus Open Radical Prostatectomy Cancer Control. European Urology, 2014, 66, 666-672.	1.9	97
70	Addressing intimacy and partner communication after breast cancer: a randomized controlled group intervention. Breast Cancer Research and Treatment, 2009, 118, 99-111.	2.5	93
71	Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. Nature Communications, 2016, 7, 11375.	12.8	93
72	Low heart rate variability and cancer-related fatigue in breast cancer survivors. Psychoneuroendocrinology, 2014, 45, 58-66.	2.7	92

#	Article	IF	CITATIONS
73	Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer. Nature Communications, 2019, 10, 1741.	12.8	90
74	Understanding the Breast Cancer Experience of African-American Women. Journal of Psychosocial Oncology, 1997, 15, 19-35.	1.2	89
75	Shared heritability and functional enrichment across six solid cancers. Nature Communications, 2019, 10, 431.	12.8	88
76	Fatigue after breast cancer treatment: Biobehavioral predictors of fatigue trajectories Health Psychology, 2018, 37, 1025-1034.	1.6	87
77	Long-term Peripheral Neuropathy in Breast Cancer Patients Treated With Adjuvant Chemotherapy: NRG Oncology/NSABP B-30. Journal of the National Cancer Institute, 2018, 110, .	6.3	85
78	Impact of Adjuvant Endocrine Therapy on Quality of Life and Symptoms: Observational Data Over 12 Months From the Mind-Body Study. Journal of Clinical Oncology, 2016, 34, 816-824.	1.6	83
79	Current state of quality of life and patient-reported outcomes research. European Journal of Cancer, 2019, 121, 55-63.	2.8	83
80	Breast Cancer Survivorship: Where Are We Today?. Advances in Experimental Medicine and Biology, 2015, 862, 1-8.	1.6	82
81	Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. Genetics in Medicine, 2020, 22, 1653-1666.	2.4	82
82	Late Cardiac Effects of Adjuvant Chemotherapy in Breast Cancer Survivors Treated on Southwest Oncology Group Protocol S8897. Journal of Clinical Oncology, 2008, 26, 1223-1230.	1.6	78
83	Cognitive Function After the Initiation of Adjuvant Endocrine Therapy in Early-Stage Breast Cancer: An Observational Cohort Study. Journal of Clinical Oncology, 2014, 32, 3559-3567.	1.6	78
84	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast–ovarian cancer susceptibility locus. Nature Communications, 2016, 7, 12675.	12.8	78
85	Quality of Life of Breast Cancer Survivors After a Recurrence: A Follow-Up Study. Breast Cancer Research and Treatment, 2004, 87, 45-57.	2.5	77
86	Decline in physical functioning in first 2Âyears after breast cancer diagnosis predicts 10-year survival in older women. Journal of Cancer Survivorship, 2013, 7, 20-31.	2.9	74
87	Breast cancer, menopause, and long-term survivorship: critical issues for the 21st century. American Journal of Medicine, 2005, 118, 136-141.	1.5	71
88	Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial. Lancet, The, 2016, 387, 857-865.	13.7	67
89	Cancer-related intrusive thoughts predict behavioral symptoms following breast cancer treatment Health Psychology, 2014, 33, 155-163.	1.6	66
90	Symptom measurement in the Breast Cancer Prevention Trial (BCPT) (P-1): psychometric properties of a new measure of symptoms for midlife women. Breast Cancer Research and Treatment, 2008, 109, 515-526.	2.5	64

#	Article	IF	CITATIONS
91	Improvements in emotion regulation following mindfulness meditation: Effects on depressive symptoms and perceived stress in younger breast cancer survivors Journal of Consulting and Clinical Psychology, 2017, 85, 397-402.	2.0	64
92	Randomized Controlled Trial of Survivorship Care Plans Among Low-Income, Predominantly Latina Breast Cancer Survivors. Journal of Clinical Oncology, 2017, 35, 1814-1821.	1.6	62
93	Health-Related Quality of Life in Axillary Node-Negative, Estrogen Receptor-Negative Breast Cancer Patients Undergoing AC Versus CMF Chemotherapy: Findings from the National Surgical Adjuvant Breast and Bowel Project B-23. Breast Cancer Research and Treatment, 2004, 86, 153-164.	2.5	61
94	Subjective or Objective Measures of Cognitive Functioning—What's More Important?. JAMA Oncology, 2016, 2, 1263.	7.1	60
95	Psychological and social aspects of breast cancer. Oncology, 2008, 22, 642-6, 650; discussion 650, 653.	0.5	58
96	Cigarette Smoking, Obesity, Physical Activity, and Alcohol Use As Predictors of Chemoprevention Adherence in the National Surgical Adjuvant Breast and Bowel Project P-1 Breast Cancer Prevention Trial. Cancer Prevention Research, 2011, 4, 1393-1400.	1.5	57
97	Psychosocial Concerns and Quality of Life in Breast Cancer Survivors. Cancer Investigation, 1999, 17, 342-348.	1.3	56
98	Responses of patients with neoplastic diseases to influenza virus vaccine. Cancer, 1978, 42, 2244-2247.	4.1	55
99	Long-Term Follow-Up of Cardiac Function and Quality of Life for Patients in NSABP Protocol B-31/NRG Oncology: A Randomized Trial Comparing the Safety and Efficacy of Doxorubicin and Cyclophosphamide (AC) Followed by Paclitaxel With AC Followed by Paclitaxel and Trastuzumab in Patients With Node-Positive Breast Cancer With Tumors Overexpressing Human Epidermal Growth	1.6	55
100	Current issues in cancer rehabilitation. Cancer, 1990, 65, 742-751.	4.1	54
101	Quality of life over 5 years after a breast cancer diagnosis among lowâ€income women: Effects of race/ethnicity and patientâ€physician communication. Cancer, 2015, 121, 916-926.	4.1	54
102	Chemotherapy-Associated Peripheral Neuropathy in Patients With Early-Stage Breast Cancer: A Systematic Review. Journal of the National Cancer Institute, 2018, 110, .	6.3	54
103	A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. Cancer Research, 2018, 78, 5419-5430.	0.9	54
104	DNA methylation age is elevated in breast tissue of healthy women. Breast Cancer Research and Treatment, 2017, 164, 209-219.	2.5	52
105	Quality of Care and Cancer Survivorship: The Challenge of Implementing the Institute of Medicine Recommendations. Journal of Oncology Practice, 2009, 5, 101-105.	2.5	51
106	Outcomes and Satisfaction After Delivery of a Breast Cancer Survivorship Care Plan: Results of a Multicenter Trial. Journal of Oncology Practice, 2015, 11, e222-e229.	2.5	51
107	Quality of Life Across the Continuum of Breast Cancer Care. Breast Journal, 2000, 6, 324-330.	1.0	49
108	Barriers to physical activity and healthy eating in young breast cancer survivors: modifiable risk factors and associations with body mass index. Breast Cancer Research and Treatment, 2013, 142, 423-433.	2.5	49

#	Article	IF	CITATIONS
109	Identifying Cancer-Related Cognitive Impairment Using the FACT-Cog Perceived Cognitive Impairment. JNCI Cancer Spectrum, 2020, 4, pkz099.	2.9	49
110	Posttraumatic growth in breast cancer survivors: does age matter?. Psycho-Oncology, 2017, 26, 800-807.	2.3	47
111	Older Breast Cancer Survivors: Factors Associated With Change in Emotional Well-Being. Journal of Clinical Oncology, 2007, 25, 1334-1340.	1.6	46
112	Post-traumatic stress symptoms in cancer survivors: relationship to the impact of cancer scale and other associated risk factors. Psycho-Oncology, 2015, 24, 643-652.	2.3	45
113	Cancer survivorship research: the challenge of recruiting adult long term cancer survivors from a cooperative clinical trials group. Journal of Cancer Survivorship, 2009, 3, 137-147.	2.9	44
114	Use of Patient-Reported Outcomes in Phase III Cancer Treatment Trials: Lessons Learned and Future Directions. Journal of Clinical Oncology, 2007, 25, 5063-5069.	1.6	42
115	Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women. Breast Cancer Research, 2016, 18, 112.	5.0	42
116	Are primary care providers prepared to care for survivors of breast cancer in the safety net?. Cancer, 2015, 121, 1249-1256.	4.1	40
117	Effects of mindfulness training on emotional and physiologic recovery from induced negative affect. Psychoneuroendocrinology, 2017, 86, 78-86.	2.7	40
118	Childhood Adversity and Inflammation in Breast Cancer Survivors. Psychosomatic Medicine, 2014, 76, 208-214.	2.0	39
119	Cognitive performance in survivors of breast cancer and markers of biological aging. Cancer, 2019, 125, 298-306.	4.1	39
120	Quality of life outcomes from the Exercise and Nutrition Enhance Recovery and Good Health for You (ENERGY)-randomized weight loss trial among breast cancer survivors. Breast Cancer Research and Treatment, 2015, 154, 329-337.	2.5	38
121	radiotherapy (CWRNRT) post mastectomy (Mx) or the addition of RNRT to whole breast RT post breast-conserving surgery (BCS) reduces invasive breast cancer recurrence-free interval (IBCR-FI) in patients (pts) with pathologically positive axillary (PPAx) nodes who are ypNO after neoadjuvant	1.6	38
122	The cognitive effects of endocrine therapy in survivors of breast cancer: A prospective longitudinal study up to 6 years after treatment. Cancer, 2019, 125, 681-689.	4.1	37
123	Biomarkers of aging associated with past treatments in breast cancer survivors. Npj Breast Cancer, 2017, 3, 50.	5.2	36
124	"Doctor, Will the Treatment You Are Recommending Cause Chemobrain?― Journal of Clinical Oncology, 2012, 30, 229-231.	1.6	35
125	Prometastatic Molecular Profiles in Breast Tumors From Socially Isolated Women. JNCI Cancer Spectrum, 2018, 2, pky029.	2.9	35
126	What Outcomes Matter to Patients. Medical Care, 2002, 40, III-11-III-19.	2.4	34

#	Article	IF	CITATIONS
127	Val66Met BDNF polymorphism as a vulnerability factor for inflammation-associated depressive symptoms in women with breast cancer. Journal of Affective Disorders, 2016, 197, 43-50.	4.1	34
128	The spectrum of <i>BRCA1</i> and <i>BRCA2</i> pathogenic sequence variants in Middle Eastern, North African, and South European countries. Human Mutation, 2019, 40, e1-e23.	2.5	34
129	Cost-effectiveness of UniversalBRCA1/2Screening. JAMA Oncology, 2015, 1, 1217.	7.1	33
130	Long-term, adverse genitourinary outcomes among endometrial cancer survivors in a large, population-based cohort study. Gynecologic Oncology, 2018, 148, 499-506.	1.4	33
131	Transcriptomeâ€wide association study of breast cancer risk by estrogenâ€receptor status. Genetic Epidemiology, 2020, 44, 442-468.	1.3	32
132	Do all patients with cancer experience fatigue? A longitudinal study of fatigue trajectories in women with breast cancer. Cancer, 2021, 127, 1334-1344.	4.1	32
133	<i>Journal of Clinical Oncology</i> Update on Progress in Cancer Survivorship Care and Research. Journal of Clinical Oncology, 2012, 30, 3655-3656.	1.6	31
134	"From Snail Mode to Rocket Ship Modeâ€: Adolescents and Young Adults' Experiences of Returning to Work and School After Hematopoietic Cell Transplantation. Journal of Adolescent and Young Adult Oncology, 2017, 6, 551-559.	1.3	31
135	Testing a biobehavioral model of fatigue before adjuvant therapy in women with breast cancer. Cancer, 2019, 125, 633-641.	4.1	31
136	Symptoms: Fatigue and Cognitive Dysfunction. Advances in Experimental Medicine and Biology, 2015, 862, 53-75.	1.6	31
137	Impact of Survivorship-Based Research on Defining Clinical Care Guidelines. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 2085-2092.	2.5	30
138	Positive Affect and Inflammatory Activity in Breast Cancer Survivors: Examining the Role of Affective Arousal. Psychosomatic Medicine, 2016, 78, 532-541.	2.0	30
139	Quality of life and symptoms in long-term survivors of colorectal cancer: results from NSABP protocol LTS-01. Journal of Cancer Survivorship, 2017, 11, 111-118.	2.9	30
140	Aging-Related Disease Risks among Young Thyroid Cancer Survivors. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 1695-1704.	2.5	30
141	Height and Body Mass Index as Modifiers of Breast Cancer Risk in <i>BRCA1</i> / <i>2</i> Mutation Carriers: A Mendelian Randomization Study. Journal of the National Cancer Institute, 2019, 111, 350-364.	6.3	30
142	Psychosocial Issues in Lung Cancer Patients (part 2). Chest, 1991, 99, 480-485.	0.8	29
143	Charting a New Course for the Delivery of High-Quality Cancer Care. Journal of Clinical Oncology, 2013, 31, 4485-4487.	1.6	29
144	Targeting Depressive Symptoms in Younger Breast Cancer Survivors: The Pathways to Wellness Randomized Controlled Trial of Mindfulness Meditation and Survivorship Education. Journal of Clinical Oncology, 2021, 39, 3473-3484.	1.6	29

#	Article	IF	CITATIONS
145	Symptoms and QOL as Predictors of Chemoprevention Adherence in NRG Oncology/NSABP Trial P-1. Journal of the National Cancer Institute, 2016, 108, djv365.	6.3	28
146	Risk Factors for Cardiovascular Disease Among Thyroid Cancer Survivors: Findings From the Utah Cancer Survivors Study. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 2468-2477.	3.6	28
147	Compliance With Patient-Reported Outcomes in Multicenter Clinical Trials: Methodologic and Practical Approaches. Journal of Clinical Oncology, 2007, 25, 5113-5120.	1.6	27
148	Depression and vasomotor symptoms in young breast cancer survivors: the mediating role of sleep disturbance. Archives of Women's Mental Health, 2015, 18, 565-568.	2.6	27
149	Expanding Our Therapeutic Options: Beta Blockers for Breast Cancer?. Journal of Clinical Oncology, 2011, 29, 2612-2616.	1.6	26
150	<i>BRCA1</i> and <i>BRCA2</i> pathogenic sequence variants in women of African origin or ancestry. Human Mutation, 2019, 40, 1781-1796.	2.5	26
151	Treatment of Nonmetastatic Breast Cancer. JAMA - Journal of the American Medical Association, 2019, 321, 1716.	7.4	26
152	Cancer-related accelerated ageing and biobehavioural modifiers: a framework for research and clinical care. Nature Reviews Clinical Oncology, 2022, 19, 173-187.	27.6	26
153	Neuropsychological studies in breast cancer: in search of chemobrain. Breast Cancer Research and Treatment, 2009, 116, 125-127.	2.5	25
154	Q&A: The 'three Ps' of cancer survivorship care. BMC Medicine, 2011, 9, 14.	5.5	25
155	How much do cancerâ€related symptoms contribute to healthâ€related quality of life in lung and colorectal cancer patients? A report from the Cancer Care Outcomes Research and Surveillance (CanCORS) Consortium. Cancer, 2015, 121, 2831-2839.	4.1	25
156	Cognitive function following breast cancer treatment and associations with concurrent symptoms. Npj Breast Cancer, 2018, 4, 25.	5.2	25
157	Methods of Assessing the Effect of Drug Therapy on Quality of Life. Drug Safety, 1990, 5, 233-242.	3.2	24
158	Evaluating Treatment Tolerability in Cancer Clinical Trials Using the Toxicity Index. Journal of the National Cancer Institute, 2020, 112, 1266-1274.	6.3	24
159	Menopause and breast cancer: Symptoms, late effects, and their management. Seminars in Oncology, 2001, 28, 274-283.	2.2	24
160	Quality-of-Life Assessment in Cancer Clinical Trials: A Status Report. Journal of the National Cancer Institute, 1992, 84, 994-995.	6.3	23
161	Assessing the quality of life of HIV infected persons: Clinical and descriptive information from studies with the hopes. Psychology and Health, 1994, 9, 93-110.	2.2	23
162	Childhood maltreatment and monocyte gene expression among women with breast cancer. Brain, Behavior, and Immunity, 2020, 88, 396-402.	4.1	23

#	Article	IF	CITATIONS
163	Polygenic risk modeling for prediction of epithelial ovarian cancer risk. European Journal of Human Genetics, 2022, 30, 349-362.	2.8	23
164	Development and Validation of a Predictive Model of Severe Fatigue After Breast Cancer Diagnosis: Toward a Personalized Framework in Survivorship Care. Journal of Clinical Oncology, 2022, 40, 1111-1123.	1.6	23
165	Dynamics of Long-Term Patient-Reported Quality of Life and Health Behaviors After Adjuvant Breast Cancer Chemotherapy. Journal of Clinical Oncology, 2022, 40, 3190-3204.	1.6	23
166	Improving Breast Cancer Quality of Care with the Use of Patient Navigators. American Surgeon, 2010, 76, 1043-1046.	0.8	22
167	Disparities in the survivorship experience among Latina survivors of breast cancer. Cancer, 2018, 124, 2373-2380.	4.1	22
168	Childhood maltreatment, psychological resources, and depressive symptoms in women with breast cancer. Child Abuse and Neglect, 2017, 72, 360-369.	2.6	21
169	Cancer-Related Cognitive Impairment in Patients With a History of Breast Cancer. JAMA - Journal of the American Medical Association, 2021, 326, 1736.	7.4	21
170	NIH State-of-the-Science Conference Statement: Role of active surveillance in the management of men with localized prostate cancer. NIH Consensus and State-of-the-science Statements, 2011, 28, 1-27.	7.0	21
171	Cancerâ€related impairments and functional limitations among longâ€term cancer survivors: Gaps and opportunities for clinical practice. Cancer, 2022, 128, 222-229.	4.1	20
172	Interaction between the physician and the older patient. , 1997, 80, 1323-1325.		19
173	Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers. British Journal of Cancer, 2019, 121, 180-192.	6.4	19
174	Patient Education as a Moderator of Psychological Distress. Journal of Psychosocial Oncology, 1988, 6, 181-197.	1.2	18
175	Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. Breast Cancer Research and Treatment, 2017, 161, 117-134.	2.5	18
176	Addressing the Survivorship Care Needs of Patients Receiving Extended Cancer Treatment. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 674-683.	3.8	18
177	Cortisol Awakening Response as a Prospective Risk Factor for Depressive Symptoms in Women After Treatment for Breast Cancer. Psychosomatic Medicine, 2017, 79, 763-769.	2.0	18
178	Long-Term Longitudinal Patterns of Patient-Reported Fatigue After Breast Cancer: A Group-Based Trajectory Analysis. Journal of Clinical Oncology, 2022, 40, 2148-2162.	1.6	18
179	Quality of Life Measures in Cancer Chemotherapy. Pharmacoeconomics, 1994, 5, 376-388.	3.3	17
180	Randomized trial to increase colorectal cancer screening in an ethnically diverse sample of firstâ€degree relatives. Cancer, 2015, 121, 2951-2959.	4.1	17

#	Article	IF	CITATIONS
181	Long-term Cardiovascular Outcomes Among Endometrial Cancer Survivors in a Large, Population-Based Cohort Study. Journal of the National Cancer Institute, 2018, 110, 1342-1351.	6.3	17
182	Economic Evaluation in the Journal of Clinical Oncology: Past, Present, and Future. Journal of Clinical Oncology, 2007, 25, 614-616.	1.6	16
183	"Winging It― How Older Breast Cancer Survivors Persist With Aromatase Inhibitor Treatment. Journal of Oncology Practice, 2016, 12, e991-e1000.	2.5	16
184	The predictive ability of the 313 variant–based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant. Genetics in Medicine, 2021, 23, 1726-1737.	2.4	16
185	Acceptability of Mobile Mammography Among Communityâ€Dwelling Older Women. Journal of the American Geriatrics Society, 1997, 45, 1365-1370.	2.6	15
186	Organizational systems used by California capitated medical groups and independent practice associations to increase cancer screening. Cancer, 2000, 88, 2824-2831.	4.1	15
187	Improving the quality of cancer care in America through health information technology. Journal of the American Medical Informatics Association: JAMIA, 2014, 21, 772-775.	4.4	15
188	What outcomes matter to patients: a physician-researcher point of view. Medical Care, 2002, 40, III11-9.	2.4	14
189	Menopause and Breast Cancer: Addressing the Secondary Health Effects of Adjuvant Chemotherapy. Journal of Clinical Oncology, 2001, 19, 3303-3305.	1.6	13
190	Doctor, Now That My Chemotherapy Treatment Is Over, When Will My "Chemofog―Lift?. Journal of Clinical Oncology, 2017, 35, 482-484.	1.6	13
191	National Outcomes in Hospitalized Patients With Cancer and Comorbid Heart Failure. Journal of Cardiac Failure, 2019, 25, 516-521.	1.7	13
192	Psychosocial issues in lung cancer patients. Cancer Treatment and Research, 1994, 72, 363-390.	0.5	13
193	Risks, benefits, and effects on quality of life of selective estrogen-receptor modulator therapy in postmenopausal women at increased risk of breast cancer. Menopause, 2008, 15, 797-803.	2.0	12
194	Improving breast cancer survivors' knowledge using a patient-centered intervention. Surgery, 2015, 158, 669-675.	1.9	12
195	Measuring cognitive complaints in breast cancer survivors: psychometric properties of the patient's assessment of own functioning inventory. Supportive Care in Cancer, 2016, 24, 4939-4949.	2.2	12
196	Correlates of quality of life in overweight or obese breast cancer survivors at enrollment into a weight loss trial. Psycho-Oncology, 2016, 25, 142-149.	2.3	12
197	Coming of Age With Cancer: Physical, Social, and Financial Barriers to Independence Among Emerging Adult Survivors. Oncology Nursing Forum, 2018, 45, 148-158.	1.2	12
198	Reproductive and gynecological complication risks among thyroid cancer survivors. Journal of Cancer Survivorship, 2018, 12, 702-711.	2.9	12

#	Article	IF	CITATIONS
199	Vulnerability to inflammation-related depressive symptoms: Moderation by stress in women with breast cancer. Brain, Behavior, and Immunity, 2021, 94, 71-78.	4.1	12
200	Primary results, NRG Oncology/NSABP B-35: A clinical trial of anastrozole (A) versus tamoxifen (tam) in postmenopausal patients with DCIS undergoing lumpectomy plus radiotherapy Journal of Clinical Oncology, 2015, 33, LBA500-LBA500.	1.6	12
201	The Status of Cancer Rehabilitation in the Late 1990s. Mayo Clinic Proceedings, 1999, 74, 939-940.	3.0	11
202	Living with Metastatic Breast Cancer. Advances in Experimental Medicine and Biology, 2015, 862, 243-254.	1.6	11
203	Special Issues in Younger Women with Breast Cancer. Advances in Experimental Medicine and Biology, 2015, 862, 9-21.	1.6	11
204	Impact of a behavioral weight loss intervention on comorbidities in overweight and obese breast cancer survivors. Supportive Care in Cancer, 2016, 24, 3285-3293.	2.2	11
205	Evaluating cognitive complaints in breast cancer survivors with the FACT-Cog and quantitative electroencephalography. Breast Cancer Research and Treatment, 2017, 166, 157-166.	2.5	11
206	Potential Mechanisms of Age Acceleration Caused by Estrogen Deprivation: Do Endocrine Therapies Carry the Same Risks?. JNCI Cancer Spectrum, 2018, 2, pky035.	2.9	11
207	Moderators of inflammation-related depression: a prospective study of breast cancer survivors. Translational Psychiatry, 2021, 11, 615.	4.8	11
208	Prostate Cancer: The Price of Early Detection. Journal of Clinical Oncology, 2001, 19, 1587-1588.	1.6	10
209	Harnessing personalised medicine to prevent late effects. Lancet Oncology, The, 2010, 11, 7-9.	10.7	10
210	Host Factors, Behaviors, and Clinical Trials: Opportunities and Challenges. Journal of Clinical Oncology, 2012, 30, 2817-2819.	1.6	10
211	Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. PLoS ONE, 2016, 11, e0158801.	2.5	10
212	Development and pilot testing of a psychosocial intervention program for young breast cancer survivors. Patient Education and Counseling, 2016, 99, 414-420.	2.2	10
213	Inflammation and attentional bias in breast cancer survivors. Brain, Behavior, and Immunity, 2017, 66, 85-88.	4.1	10
214	Endocrine and Metabolic Diseases Among Colorectal Cancer Survivors in a Population-Based Cohort. Journal of the National Cancer Institute, 2020, 112, 78-86.	6.3	10
215	Cognitive Impairment in Patients With Breast Cancer: Understanding the Impact of Chemotherapy and Endocrine Therapy. Journal of Clinical Oncology, 2020, 38, 1871-1874.	1.6	10
216	Randomized Controlled Phase II Evaluation of Two Dose Levels of Bupropion Versus Placebo for Sexual Desire in Female Cancer Survivors: NRG-CC004. Journal of Clinical Oncology, 2022, 40, 324-334.	1.6	10

#	Article	IF	CITATIONS
217	Pediatric Cancer Survivorship: The Childhood Cancer Survivor Study—Editor's Foreword. Journal of Clinical Oncology, 2009, 27, 2307-2307.	1.6	9
218	Changes in Body Mass Index and Physical Activity Predict Changes in Vitality During a Weight Loss Trial in Breast Cancer Survivors. Annals of Behavioral Medicine, 2018, 52, 999-1009.	2.9	9
219	Current US Cancer Statistics: Alarming Trends in Young Adults?. Journal of the National Cancer Institute, 2019, 111, 1241-1242.	6.3	9
220	Prediction of Breast Cancer Treatment–Induced Fatigue by Machine Learning UsingÂGenome-Wide Association Data. JNCI Cancer Spectrum, 2020, 4, pkaa039.	2.9	9
221	NRG Oncology/NSABP B-51/RTOG 1304: Phase III trial to determine if chest wall and regional nodal radiotherapy (CWRNRT) post mastectomy (Mx) or the addition of RNRT to breast RT post breast-conserving surgery (BCS) reduces invasive breast cancer recurrence free interval (IBCRFI) in patients (pts) with positive axillary (PAx) nodes who are ypNO after neoadjuvant chemotherapy (NC)	1.6	9
222	Journal of Clinical Oncology, 2017, 35, 1955397 195589. Incorporating the Risk for Subsequent Primary Cancers Into the Care of Adult Cancer Survivors. JAMA - Journal of the American Medical Association, 2020, 324, 2493.	7.4	9
223	Behavioral Science Research in the Cooperative Group Setting: the Southwest Oncology Group Experience. Journal of the National Cancer Institute, 2000, 92, 1381-1387.	6.3	8
224	Health-Related Quality of Life Measurement in Symptom Management Trials. Journal of the National Cancer Institute Monographs, 2007, 2007, 47-52.	2.1	8
225	Screening for Depression in Younger Breast Cancer Survivors: Outcomes From Use of the 9-item Patient Health Questionnaire. JNCI Cancer Spectrum, 2021, 5, pkab017.	2.9	8
226	Socioeconomic Status and Inflammation in Women with Early-stage Breast Cancer: Mediation by Body Mass Index. Brain, Behavior, and Immunity, 2022, 99, 307-316.	4.1	8
227	Improving colorectal cancer screening rates in a managed care health plan: recruitment of provider organizations for a randomized effectiveness trial. Cancer Epidemiology Biomarkers and Prevention, 2003, 12, 824-9.	2.5	8
228	Practice-Changing Strategies to Deliver Affordable, High-Quality Cancer Care: Summary of an Institute of Medicine Workshop. Journal of Oncology Practice, 2013, 9, 54s-59s.	2.5	7
229	Cancer Survivors: A Look Backward and Forward. Journal of Oncology Practice, 2014, 10, 289-293.	2.5	7
230	Improving the Quality and Value of Cancer Care: A Work in Progress—The 2016 Joseph V. Simone Award and Lecture. Journal of Oncology Practice, 2016, 12, 876-879.	2.5	7
231	Painful Hands and Feet After Cancer Treatment: Inflammation Affecting the Mind-Body Connection. Journal of Clinical Oncology, 2016, 34, 649-652.	1.6	7
232	Communicating Risks of Adjuvant Chemotherapy for Breast Cancer: Getting Beyond the Laundry List. Journal of Oncology Practice, 2019, 15, e98-e109.	2.5	7
233	The Effects of Lifetime Estrogen Exposure on Breast Epigenetic Age. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 1241-1249.	2.5	7
234	DNA Methylation, Aging, and Cancer Risk: A Mini-Review. Frontiers in Bioinformatics, 2022, 2, .	2.1	7

#	Article	IF	CITATIONS
235	Disparities in breast cancer care and research: report from a Breast Cancer Research Foundation sponsored workshop, $9\hat{a}\in$ 10 October 2014. Npj Breast Cancer, 2015, 1, 15013.	5.2	6
236	Motivations associated with physical activity in young breast cancer survivors. Psychology, Health and Medicine, 2015, 20, 393-399.	2.4	6
237	Delivering Patient-Centered Care in the Setting of Advanced Cancer. JAMA Oncology, 2015, 1, 430.	7.1	6
238	Quality of Care, Including Survivorship Care Plans. Advances in Experimental Medicine and Biology, 2015, 862, 255-269.	1.6	6
239	Goal disturbance in early-stage breast cancer survivors. Journal of Psychosocial Oncology, 2019, 37, 478-493.	1.2	6
240	Toxicity Index, Patient-Reported Outcomes, and Early Discontinuation of Endocrine Therapy for Breast Cancer Risk Reduction in NRG Oncology/NSABP B-35. Journal of Clinical Oncology, 2021, 39, 3800-3812.	1.6	6
241	Current practice patterns and gaps in guideline-concordant breast cancer survivorship care. Journal of Cancer Survivorship, 2023, 17, 906-915.	2.9	6
242	The role of hormones in breast carcinogenesis: Issues of relevance to female childhood cancer survivors. Medical and Pediatric Oncology, 2001, 36, 514-518.	1.0	5
243	Comparison of the impact of cancer between British and US long-term non-Hodgkin lymphoma survivors. Supportive Care in Cancer, 2017, 25, 739-748.	2.2	5
244	Antimullerian Hormone as a Serum Biomarker for Risk of Chemotherapy-Induced Amenorrhea. Journal of the National Cancer Institute, 2021, 113, 1105-1108.	6.3	5
245	Final updated results of the NRG Oncology/NSABP Protocol P-2: Study of Tamoxifen and Raloxifene (STAR) in preventing breast cancer Journal of Clinical Oncology, 2015, 33, 1500-1500.	1.6	5
246	The price of anticancer intervention. Lancet Oncology, The, 2002, 3, 575-579.	10.7	4
247	Breast cancer risk: is postmenopausal hormone therapy ever safe?. Menopause, 2005, 12, 653-655.	2.0	4
248	Quality of Life Assessment in Breast Cancer: When Does it Add Prognostic Value for Survival?. Breast Journal, 2011, 17, 569-570.	1.0	4
249	Challenges and Opportunities in Delivering High-Quality Cancer Care: A 2016 Update. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, e294-e300.	3.8	4
250	Understanding the impact of breast cancer adjuvant endocrine therapy on cognitive function: a work in progress. British Journal of Cancer, 2016, 114, 953-955.	6.4	4
251	Health burden in cancer survivors: below the tip of the iceberg. Nature Reviews Clinical Oncology, 2019, 16, 467-468.	27.6	4
252	NRG Oncology/NSABP B-47 menstrual history study: impact of adjuvant chemotherapy with and without trastuzumab. Npj Breast Cancer, 2021, 7, 55.	5.2	4

#	Article	IF	CITATIONS
253	Quality of Life Research: Clinical Applications. , 1998, 97, 1-12.		4
254	Professional Attitudes Toward Hospice Care. Journal of Pain and Palliative Care Pharmacotherapy, 1985, 1, 1-15.	0.2	4
255	Moving the Translational Needle in Breast Cancer Survivorship: Connecting Intervention Research to Clinical Practice. Journal of Clinical Oncology, 2022, 40, 2069-2073.	1.6	4
256	Health Services Utilisation in Breast Cancer Survivors in Taiwan. Scientific Reports, 2014, 4, 7466.	3.3	3
257	Quality of Posttreatment Care Among Breast Cancer Survivors in the University of California Athena Breast Health Network (Athena). Clinical Breast Cancer, 2016, 16, 356-363.	2.4	3
258	Seven-year follow-up for energy/vitality outcomes in early stage Hodgkin's disease patients treated with subtotal lymphoid irradiation versus chemotherapy plus radiation: SWOG S9133 and its QOL companion study, S9208. Journal of Cancer Survivorship, 2017, 11, 32-40.	2.9	3
259	The inflammation complication: New evidence in cancer-related cognitive impairment. Brain, Behavior, and Immunity, 2019, 81, 6-7.	4.1	3
260	Evidence map of ductal carcinoma in situ management options. Menopause, 2019, 26, 1250-1258.	2.0	3
261	The Hazards of Assessing the Carcinogenicity of Agents. Journal of the National Cancer Institute, 2020, 112, 1-2.	6.3	3
262	The Survivorship Care Plan: What, Why, How, and for Whom. , 2007, , 287-293.		3
263	NRG-GI004/SWOG-S1610: Colorectal cancer metastatic divinit immuno-therapy (COMMIT) studya€ A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (mCRC) Journal of Clinical	1.6	3
264	The impact of reproductive factors on DNA methylation-based telomere length in healthy breast tissue. Npj Breast Cancer, 2022, 8, 48.	5.2	3
265	Healthâ€related quality of life outcomes after neoadjuvantÂchemoradiotherapy for rectal cancer in <scp>NRG</scp> ÂOncology/ <scp>NSABP</scp> Râ€04. Cancer, 2022, 128, 3233-3242.	4.1	3
266	Survival in Acute Leukemia in Elderly Patients. Journal of the American Geriatrics Society, 1991, 39, 102-102.	2.6	2
267	Breast cancer, menopause, and long-term survivorship: Critical issues for the 21st century. American Journal of Medicine, 2005, 118, 1410.	1.5	2
268	Adjuvant Therapy for Breast Cancer: No Pain, No Gain?. Breast Diseases, 2006, 16, 320-322.	0.0	2
269	Estimating the Human Costs of Cancer Survivorship in Children. Annals of Internal Medicine, 2010, 152, 465.	3.9	2
270	Can We Find the Positive in Negative Clinical Trials?. Journal of the National Cancer Institute, 2019, 111, 637-638.	6.3	2

#	Article	IF	CITATIONS
271	Association of APOE4 genotype and treatment with cognitive outcomes in breast cancer survivors over time. Npj Breast Cancer, 2021, 7, 112.	5.2	2
272	Cancer Survivors: A Physician's Perspective. , 2007, , 1-7.		2
273	Results of the exercise and nutrition to enhance recovery and good health for you (ENERGY) trial: A behavioral weight loss intervention in overweight or obese breast cancer survivors Journal of Clinical Oncology, 2015, 33, 9506-9506.	1.6	2
274	Visualizing adverse events in clinical trials using correspondence analysis with R-package visae. BMC Medical Research Methodology, 2021, 21, 244.	3.1	2
275	Younger women are more susceptible to inflammation: A longitudinal examination of the role of aging in inflammation and depressive symptoms. Journal of Affective Disorders, 2022, 310, 328-336.	4.1	2
276	Professional Attitudes Toward Hospice Care. Journal of Pain and Palliative Care Pharmacotherapy, 1985, 1, 1-15.	0.2	1
277	Identifying Tools and Strategies to Provide Quality Oncology Care. Journal of Oncology Practice, 2013, 9, 125-127.	2.5	1
278	Reply to I.E. Haines. Journal of Clinical Oncology, 2014, 32, 1978-1978.	1.6	1
279	Reply to P. Tralongo et al. Journal of Clinical Oncology, 2017, 35, 3517-3517.	1.6	1
280	"Improving to where?â€ŧ treatment-related health risks and perceptions of the future among adolescents and young adults after hematopoietic cell transplantation. Supportive Care in Cancer, 2019, 27, 623-630.	2.2	1
281	Applying the Toxicity Index to Patient-Reported Symptom Data: An Example Using the European Organization for Research and Treatment of Cancer Colorectal Cancer–Specific Quality of Life Questionnaire. Clinical Therapeutics, 2021, 43, 1245-1252.	2.5	1
282	NRG Oncology/NSABP B-51/RTOG 1304: Phase III trial to determine if chest wall and regional nodal radiotherapy (CWRNRT) post mastectomy (Mx) or the addition of RNRT to breast RT post breast-conserving surgery (BCS) will reduce invasive cancer events in patients (pts) with positive axillary (Ax) nodes who are ypNO after neoadjuvant chemotherapy (NC) Journal of Clinical Oncology,	1.6	1
283	2015, 33, TPS11112-TPS11112. Quality of Life and Cancer Rehabilitation. Rehabilitation Oncology, 1999, 17, 9-11.	0.5	1
284	Patient-reported outcomes and behavioral risk factors as predictors of chemoprevention adherence among women in the National Surgical Adjuvant Breast and Bowel Program (NSABP) Breast Cancer Prevention P-1 trial Journal of Clinical Oncology, 2014, 32, 1512-1512.	1.6	1
285	Behavioral and health outcomes from the NRG Oncology/NSABP B-36 trial comparing two different adjuvant therapy regimens for early-stage node-negative breast cancer. Breast Cancer Research and Treatment, 2022, 192, 153-161.	2.5	1
286	Evaluating the Association of Adverse Events and Patient-Reported Symptoms to Endocrine Therapy Tolerability. Journal of Clinical Oncology, 2022, 40, 430-431.	1.6	1
287	A Survivorship Educational Tool for Latino Adolescent and Young Adult Cancer Survivors. Health Promotion Practice, 2022, 23, 861-873.	1.6	1
288	A mixed method study of medical oncologists' perceived barriers and motivators to addressing long-term effects in breast cancer survivors. Breast Cancer Research and Treatment, 2022, 194, 699-707.	2.5	1

#	Article	IF	CITATIONS
289	Breast Cancer Rehabilitation and Survivorship: Cost, Quality, and Lessons Learned. Seminars in Breast Disease, 2008, 11, 148-153.	0.0	0
290	Relevant Endpoints for Advanced Breast Cancer Patients. Breast, 2011, 20, S18.	2.2	0
291	Editorial: Changing of the Guard at the Journal of the National Cancer Institute. Journal of the National Cancer Institute, 2017, 109, .	6.3	Ο
292	Implementing the Survivorship Care Plan: A Strategy for Improving the Quality of Care for Cancer Survivors. , 2010, , 557-561.		0
293	Optimizing Health: Oncology Care. , 2011, , 205-221.		0
294	The Role of Rehabilitation in the Older Patient with Cancer. , 2012, , 207-212.		0
295	node-negative, HER2-low invasive breast cancer Journal of Clinical Oncology, 2012, 30,	1.6	0
296	Implementing the Survivorship Care Plan. , 2015, , 644-650.		0
297	Fatigue in long-term non-Hodgkin lymphoma survivors Journal of Clinical Oncology, 2015, 33, e20628.	1.6	Ο
298	Primary results, NRG Oncology/NSABP B-35: A clinical trial of anastrozole (A) versus tamoxifen (tam) in postmenopausal patients with DCIS undergoing lumpectomy plus radiotherapy Journal of Clinical Oncology, 2015, 33, LBA500-LBA500.	1.6	0
299	NRG Oncology/NSABP B-51/RTOG 1304: Phase III trial to determine if chest wall and regional nodal radiotherapy (CWRNRT) post mastectomy (Mx) or the addition of RNRT to breast RT post breast-conserving surgery (BCS) reduces invasive breast cancer recurrence free interval (IBCRFI) in patients (pts) with positive axillary (PAx) nodes who are ypN0 after neoadjuvant chemotherapy (NC)	1.6	0
300	Abstract P2-11-06: Differential gene expression patterns in healthy breast tissue exhibiting epigenetic age acceleration. Cancer Research, 2022, 82, P2-11-06-P2-11-06.	0.9	0
301	Abstract P3-18-04: Evaluating <b>de</b> -escalation of <b>b</b> reast <b>r</b> adiation ( <b>DEBRA</b> ) following lumpectomy for breast conservative treatment of stage 1, hr+, HER2-, RS â‰ <b>\$</b> 8 breast cancer: NRG-BR007 a phase III trial. Cancer Research, 2022, 82, P3-18-04-P3-18-04.	0.9	0